# US 2018/0021289 A1 · Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021289 A1
- Document ID: US20180021289A1
- Status: Published application
- Kind: A1
- Application number: 15/723,749
- Filed: 2017-10-03
- Published: 2018-01-25
- Earliest claimed: 2013-08-26
- Assignees: FWP IP ApS
- Applicants: FWP IP ApS
- Inventors: Christin GALETZKA; Chris RUNDFELDT; Roland RUPP; Peder M. ANDERSEN
- Web page: https://patentgrep.com/patent/US20180021289A1

## CPC

- A61K 31/225: Polycarboxylic acids
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/2009: {Inorganic compounds}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/28: Dragees; Coated pills or tablets {, e.g. with film or compression coating (A61K9/2072 takes precedence, e.g. partially coated tablets A61K9/2072, coated multilayer tablets A61K9/2086, tablets with drug-coated core A61K9/209)}
- A61K 9/2846: {Poly(meth)acrylates}
- A61P 17/06: Antipsoriatics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to pharmaceutical compositions containing dimethyl fumarate (DMF). More specifically, the present invention relates to a pharmaceutical composition for oral use in treating psoriasis by administering a low daily dosage in the range of 375 mg±5% dimethyl fumarate, wherein the pharmaceutical formulation is in the form of an erosion matrix tablet.

## Claims

### Claim 1

A pharmaceutical composition for oral use in treating psoriasis, wherein said composition is in the form of an erosion matrix tablet comprising a tablet core and one or more coating(s), wherein the tablet core comprises
i) 10 to 80% by weight dimethyl fumarate as an active substance, and
ii) 1 to 50% by weight of one or more rate-controlling agents,
wherein at least one of the one or more coating(s) is an enteric coating applied at a level of 1.5 to 3.5% by weight of the core, and
wherein the dose of dimethyl fumarate to be administered is 375 mg±5% per day.

### Claim 2 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the dose to be administered is 375 mg per day.

### Claim 3 (depends on 1, 2)

The pharmaceutical composition according to claim 1 or 2, wherein the tablet core comprises
i) to 60% by weight of dimethyl fumarate; and
ii) 3 to 40% by weight of one or more rate-controlling agents.

### Claim 4 (depends on 3)

The pharmaceutical composition according to claim 3, wherein the rate-controlling agent is a water-soluble polymer.

### Claim 5 (depends on 1, 2, 3, 4)

The pharmaceutical composition according to any one of claims 1-4, wherein the rate-controlling agent is a cellulose polymer or a cellulose derivative or a mixture thereof.

### Claim 6

The pharmaceutical composition according to any one of the previous claims, wherein the rate-controlling agent is selected from the group comprising hydroxypropyl cellulose, hydroxypropyl methyl cellulose (HPMC), methyl cellulose, carboxymethyl cellulose and mixtures thereof.

### Claim 7 (depends on 6)

The pharmaceutical composition according to claim 6, wherein the rate-controlling agent is hydroxypropyl cellulose.

### Claim 8

The pharmaceutical composition according to any one of the preceding claims, wherein the tablet core further comprises a binder.

### Claim 9 (depends on 8)

The pharmaceutical composition according to claim 8, wherein the binder is lactose.

### Claim 10

The pharmaceutical composition according to any one of the preceding claims, wherein the tablet core comprises:
i) 35-55% by weight of dimethyl fumarate;
ii) 3-12% by weight of hydroxypropyl cellulose; and
iii) 40-60% by weight of lactose.

### Claim 11

The pharmaceutical composition according to any one of the preceding claims, wherein the tablet core comprises:
i) 40-50% by weight of dimethyl fumarate;
ii) 3-12% by weight of hydroxypropyl cellulose; and
iii) 45-55% by weight of lactose.

### Claim 12

The pharmaceutical composition according to any one of the preceding claims, wherein the tablet core comprises:
i) 42-48% by weight of dimethyl fumarate;
ii) 3-10% by weight of hydroxypropyl cellulose; and
iii) 45-52% by weight of lactose.

### Claim 13 (depends on 11, 12)

The pharmaceutical composition according to claim 11 or 12, wherein the amount of hydroxypropyl cellulose is 3-6% by weight.

### Claim 14

The pharmaceutical composition according to any one of the preceding claims, wherein the tablet core further comprises 0.15-0.7% by weight of magnesium stearate and, optionally, 0.05 to 0.25% by weight of silicon dioxide.

### Claim 15

The pharmaceutical composition according to any one of the preceding claims for administration once, twice or three times daily.

### Claim 16

The pharmaceutical composition according to any one of the preceding claims for the treatment of mild to moderate, moderate to severe, or severe plaque psoriasis.
